Stoke Therapeutics, Inc.
STOK · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.22 | 0.26 | -0.32 | -0.21 |
| FCF Yield | -14.61% | -35.73% | -9.98% | -7.73% |
| EV / EBITDA | -4.76 | -0.37 | -2.41 | -8.83 |
| Quality | ||||
| ROIC | -43.35% | -56.92% | -41.91% | -37.81% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 0.00% |
| Cash Conversion Ratio | 0.98 | 0.77 | 0.32 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | 43.37% | – | – | – |
| Free Cash Flow Growth | -5.29% | -130.78% | 47.39% | -57.40% |
| Safety | ||||
| Net Debt / EBITDA | 1.24 | 1.69 | 1.08 | 1.72 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -717.21 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.32 | 0.00 |
| Cash Conversion Cycle | -198.27 | -128.17 | 1,066.97 | -390.37 |